This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Medical Crossfire<sup>®</sup>: Overcoming Obstacles and Improving Patient Access to PCSK9 Inhibitors: A Team-Based Approach

Medical Crossfire®: Overcoming Obstacles and Improving Patient Access to PCSK9 Inhibitors: A Team-Based Approach



Time to Complete

1 hour


December 28, 2017


December 28, 2018
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Nurse Practitioners

Accredited Provider

Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)

Commercial Supporter

Supported by an educational grant from Amgen Inc.

Program Description

This activity will serve as a call to action and will bring together a cardiologist, a specialty NP, a patient advocate, and a managed care representative to address the limited access to PCSK9 inhibitors. This multidisciplinary panel will unite to discuss this issue and raise awareness in hopes of changing policies to allow more widespread access to PCSK9 inhibitors.

Intended Audience

The educational design of this activity addresses the needs of lipidologists, cardiologists, and specialty allied health professionals with an interest in the diagnosis and management of hypercholesterolemia.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Identify high-risk individuals, including those with residual ASCVD risk such as familial hypercholesterolemia, diabetic dyslipidemia, and/or statin intolerance who would benefit for PCSK9 therapy
  • Summarize the evidence on the risks and benefits of new and emerging hypercholesterolemia therapies to guide treatment and management decisions for patients with hypercholesterolemia who are not at goal
  • Develop effective strategies for patient-centered hypercholesterolemia management including patient education, medication risks/benefits, adherence, and lifestyle modifications
  • Explain how to implement a team-based approach to improve patient access and adherence to PCSK9 inhibitors

Disclosure of Conflicts of Interest Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Harold E. Bays, MD, FTOS, FACE, FNLA
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Dr. Bays discloses the following:
Grant/Research Support: Amarin, Amgen, Alere, Allergan, Arisaph, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catabasis, Dr. Reddy, Eisai, Elcelyx, Eli Lilly, Esperion, Ferrer/Chiltern, Gemphire, Gilead, GSK, iSpecimen, Janssen, Johnson and Johnson, Kowa, Merck, Necktar, Nichi-Iko, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, Selecta, Takeda, and TIMI

Consultant/Advisor: Alnylam, Akcea, Amgen, AstraZeneca, Eisai, Eli Lilly, Esperion, Ionis (ISIS), Janssen, Johnson and Johnson, Kowa, Merck, Novartis, Prosciento, Regeneron, and Sanofi

Speaker: Amarin, Amgen, Eisai, Kowa, Orexigen, Regeneron, and Sanofi

Kevin C. Maki, PhD
Chief Scientist
Midwest Biomedical Research Center for Metabolic and Cardiovascular Health
Glen Ellyn, IL

Dr. Maki discloses the following:
Consultant/Speaker: Amgen, AstraZeneca, and Kowa Pharmaceuticals America, Inc.
Grant/Research Support: Amgen and Regeneron.

Independent Consult and Educator
Immediate Past President, National Lipid Association
Past President Preventive Cardiovascular Nurses Association
University of Pennsylvania
West Chester, PA

Ms. Ross discloses the following:
Speaker: Amarin, Amgen, Sanofi, Regeneron, Kaneka America, and KOWA

Catherine Davis Ahmed, MBA
Patient Advocate
Vice President, Policy and Outreach
FH Foundation
Pasadena, CA

Ms. Ahmed has no relevant financial relationships with commercial interests to disclose.

Accredited Provider Disclosure

Global Education Group
Planning StaffLindsay Borvansky; Andrea Funk; and Liddy Knight have no relevant financial relationships with commercial interests to disclose.

Publishing Staff Disclosures

Physicians' Education Resource®, LLC (PER®)
Planning StaffDavid Heckard; Maryjo Dixon, RPh; Neelam Davis, PharmD; and Kathleen Bowen have no relevant financial relationships with commercial interests to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




CE for Nurse Practitioners

Accreditation Statement

Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024

Designation Statement

This activity is accredited for 1.00 contact hour which includes 0.00 hour(s) of pharmacology.

Activity ID #2471E

This activity was planned in accordance with AANP CE Standards and Policies.

Disclosure of Unlabeled Use

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue